Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Deals Business Strategies

Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA

Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.

Clinical Trials FDA

Podcast: Novartis’s $9.7bn Gamble; Higher Drug Prices Post-Brexit? Jefferies Highlights

Join the London-based Eleanor Malone, Andrew McConaghie and Kevin Grogan as they review some of the most eyecatching stories in pharma and healthcare.

Europe Brexit

US Trastuzumab Competition Heats Up

Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.

Biosimilars Launches
See All

Company Information

UsernamePublicRestriction

Register